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ABSTRACT
Transcription activator like effector nucleases (TALENs) is a new and powerful technique in
genetic engineering that can delete deleterious genes or add beneficial genes to organisms. It is
being widely studied to improve crops and livestock, and is also being investigated clinically.
Comparing the details of how both TALENs and its competitor, CRISPR-Cas9, function, reveals
the potential advantages of TALENs. The growing literature, besides covering the scientific and
technical aspects of TALENs, also includes pertinent information on regulatory aspects and the
public’s perception and acceptance of TALENs.

For several decades researchers have been benefiting mankind with biotechnology and
genetic engineering. These techniques include editing genes to eliminate undesired traits, and
editing or adding genes to incorporate desired traits in organisms. (Engelhaupt 2012). When a
new development or technique in vital fields of research like these become important enough to
generate its own substantial literature, librarians and information specialists need to become
aware of this field and its literature so they can adequately serve their students, scientists,
researchers, and patrons who may need information about this field.

An innovation in gene editing is the versatile technique, transcription activator like effector
nucleases, commonly known by its abbreviation TALENs. This still developing technique is
showing its potential by being applied to develop improved livestock, and crops, such as
soybeans with no trans fats (Pennisi 2016a), and has also already been applied clinically saving
the lives of two infants with leukemia (Cross 2017).
Another gene editing technique and the main competitor to TALENs is CRISPR-Cas9.
CRISPR which stands for clustered regularly interspaced palindromic repeats, and Cas9 which
stands for CRISPR associated protein 9, has generated thousands of publications, and has been
described in the library literature (Butler 2016). The number 9 is simply the designation for one
member, the most useful one, of this family of proteins. To fully understand the applications, and
potential advantages of TALENs compared to the more well-known CRISPR-Cas9, we need to
understand the details of each of these techniques to see their strengths and weaknesses.
First, we need to start with a brief primer on genes and the genetic code, hopefully just a
review for many readers. We have known for decades that DNA, the genetic material, the stuff
of genes, is a long chain where each link contains one of 4 different building blocks. These
building blocks, usually referred to as bases, are commonly abbreviated as A, C, G, and T. The
complete DNA of an organism is known as its genome. The exact order of these bases and the
direction in which they are read determines what each gene will produce. The main product of
genes are proteins which are the visible stuff of organisms, and also enzymes, the proteins that
are the amazingly efficient biological catalysts that build and maintain the structures of
organisms, and are responsible for the chemical reactions that maintain life. Proteins consist of
chains of amino acids, and each amino acid is coded by a specific three letter sequence (codon)
of DNA bases.
TALENs are based on a discovery made when Xanthomonas, a well-known bacterium,
pathogenic to many plant species, was being investigated (Bonas et al 1989). This bacterium
causes a plant’s cells to grow abnormally large. In the early 2000’s researchers determined how
Xanthomonas causes this damage (Penissi 2012). This bacterium produces proteins called
transcription activator like effectors (TALEs) that bind to specific DNA sequences in the
affected plant, and then adversely affect expression of the plant’s gene.
Each TALE consists of a string of nearly identical small protein units, each unit containing 33
to 35 amino acids (Chandrasegaran & Carroll 2016). The only difference in the sequence of

amino acids within these units is at positions 12 and 13 which is variable. Each of these variable
units recognizes and binds to one of the four bases in DNA. Most TALEs contain between 13
and 28 of these small protein units. Figure 1 schematically shows a portion of a TALE binding to
a portion of a DNA sequence. The TALE protein units that bind to each of the four DNA bases
are shown in different colors. The DNA bases are indicated by their letters.

Figure 1 A representative portion of a TALE bound to its corresponding DNA

A….....C……..G…... T
The breakthrough in the practical application of TALEs to genetic manipulation occurred
when two discoveries were made. The first is that these protein units can easily and
inexpensively be synthesized (Pannisi 2012) then joined together so that synthetic TALEs can be
created to recognize and target any desired sequence of DNA. The second discovery is that an
enzyme that cuts DNA, known as a nuclease, can be attached to the TALE (Pannisi 2012). This
combination of a synthetic TALE with its attached nuclease is a transcription activator like
effector nuclease (TALEN). This targeting can be done in living cells, cultured cells, stem cells,
or fertilized eggs (Chandrasegaran & Carroll 2016).
After the nuclease cuts DNA, the cell has naturally occurring repair mechanisms which are
enzymes that rejoin the broken strands of DNA. This repair mechanism is error prone, and
sometimes the repair is done incorrectly and a mutation, which is a change in the DNA, results.
The most common types of mutations are the insertion of a base, deletion of a base, or
substituting one base for another. Here is a simple example of an insertion mutation and its effect
on a gene.
Figure 2a shows the first five amino acids (UniProtKB) and their corresponding codons
(Nelson & Cox 2008) in one of the subunits of the protein, human hemoglobin. To make it easier
to visualize the relationships between the codons and their corresponding amino acids, each of
these codons are a different color.

Figure 2a Human Hemoglobin Sequence
DNA:
ATGGTACTCAGTCCAGCG
Amino Acid: M.….V…….L…....S…....P…....A

Now suppose that this DNA is cut by a nuclease at the second C, and when this break is
repaired a mutation occurs, an extra base, T, is inserted after the second C. Figure 2b shows this
new mutated sequence. The newly introduced codon TAG does not code for any amino acid.
Instead it is a signal to stop the growth of this chain of amino acids, which means that no protein
is produced. Deletion and substitution mutations can produce the same effect, inactivating the
expression of a gene. While introducing this particular mutation in humans would be fatal, there
are situations where inactivating a gene is advantageous. One such application where a mutant is
deliberately selected after a TALEN is applied, is inactivating a gene in wheat that makes this
plant susceptible to a mildew infection (Pennisi 2016a). Another application of a TALEN is
turning off two genes in soybeans to allow the beans to produce healthier cooking oil (Chang
2017, Pennisi 2016a).

Figure 2b Mutated Human Hemoglobin Sequence
DNA:
ATGGTACTCTAGTCCAGCG
Amino Acid: M…….V…….L

When a TALEN cuts DNA, instead of simply allowing the organism’s repair mechanism to
rejoin the broken strands of DNA, an additional DNA sequence corresponding to a desired gene
can be added and then be incorporated into the organism’s genome. A real-life application being
investigated using this technique is correcting the genetic defect in sickle cell anemia (Tasan et
al. 2016). In this disease a mutation of a single base changes a codon for the normal amino acid
glutamic acid to the codon for another amino acid, valine. This change adversely affects the
function of hemoglobin and the health of people stricken with this disease (Nelson & Cox 2008).
The deleterious gene can be eliminated and a corrected gene added in its place.

Similar to the discovery of TALEs in the late 1980’s, in the 1990‘s researchers observed
something strange and unexpected in the DNA of bacteria. On each side of some genes they
found short sequences of DNA that did not code for any amino acids. These sequences read the
same in either direction, that is, they were palindromes. These unexpected sequences were
named clustered regularly interspaced palindromic repeats (CRISPR). CRISPRs aroused interest
because if they were not coding for proteins, what could be their role? A closer examination of
the genes between the CRISPRs showed they were DNA sequences from viruses. During a
previous viral infection, the bacteria had incorporated some of the viral DNA. Yes, bacteria, not
just animals, can be infected with viruses.
The CRISPR sequences that surrounded the viral DNA formed an immune system for the
bacteria, so the next time this virus infected the bacteria, the bacteria would be able to defend
against it. CRISPRs frame the viral DNA sequences and are a recognition site to signal Cas9 to
perform its role, which as we will see below is to cut DNA.
Here is where a second class of molecules comes into play, RNAs. RNAs are a family of
substances chemically related to DNA, and are part of the cellular machinery that converts the
genetic code from DNA to biosynthesize proteins. A key property of both DNA and RNA is that
bases on one chain pair with bases on another chain. Specifically, A is attracted to and pairs with
T, and C is attracted to and pairs with G. These attractions can be between two chains of DNA,
two chains of RNA, or two chains, one consisting of DNA and another of RNA. The only
difference in this pairing is a slight one. In RNA the chemically similar base known as U
substitutes for T.
When a virus that had previously infected the bacteria invades again, the bacteria’s immune
system produces two RNAs. One RNA containing a sequence based on the CRISPR sequence
fits into Cas9. The second RNA which also fits into Cas9 matches the viral DNA that was stored
between two CRISPR sequences. Matching means that the RNA sequence consists of bases,
where each base pairs with the corresponding base on DNA, as shown in Figure 3 which is a
partial sequence of a DNA RNA chain.

Figure 3 A Viral DNA RNA Pairing
Viral DNA …..A…..C…..G…..T…..G…..C…..
….. ….. ….. ….. ….. ….. …..
RNA
U G C A C G

Since this second RNA matches the DNA sequence of the invading virus, in addition to fitting
into Cas9, it also binds to the DNA of the invading virus. The combination of Cas9 with its two
RNAs bound to the invading viral DNA activates Cas9 enabling it to perform its role, which is to
cut the DNA of the invading virus, inactivating it. Cas9 is a nuclease.
The breakthrough in CRISPR-Cas9 was the discovery that this system can be engineered to
make it independent of having to first recognize either CRISPR or viral DNA sequences.
Researchers were able to synthesize guide RNAs. These RNAs while still being able to fit into
Cas9 could also contain any additional desired RNA, specifically sequences that match the DNA
sequences of genes that they wanted to target and modify. Like TALENs, this targeting can be
done in living cells, cultured cells, stem cells, or fertilized eggs (Chandrasegaran & Carroll
2016).
Similar to when the TALEN nuclease cuts DNA, when Cas9 cuts DNA, the cell’s naturally
occurring repair mechanisms rejoin the broken strands of DNA. Just like in TALENs, this repair
mechanism is error prone, and sometimes the repair is done incorrectly and a mutation results.
Also, as with TALENs, an additional DNA sequence corresponding to a desired gene can be
added and then be incorporated into the organism’s genome.
Another gene editing technique, an older one known as zinc fingers, is used less often because
it is difficult to design. It is also more expensive because a single company controls almost all of
the intellectual property rights (Pennisi 2012).
A major challenge in applying TALENs is that while TALENs are designed to target a
specific and desired DNA sequence, other places on the genome may have a similar DNA
sequence, causing the TALEN to also bind at this additional location. This off-target binding
may produce undesired and unpredictable consequences when the TALEN’s nuclease cuts DNA
at this unintended location (Chandrasegaran & Carroll 2016). This imprecision may have
evolved because of the ongoing evolutionary battle between the invading Xanthomonas, where
its TALE attaches to the plants genome causing disease, and the plants’ response to this invasion.
A plant may respond to this invasion by evolving, changing its DNA sequence at the site targeted
by the TALE. A Xanthomonas containing a TALE with the ability to bind to this new and nonexact sequence will have an evolutionary advantage (Chandrasegaran & Carroll 2016).

A similar phenomenon also takes place in CRISPR-Cas9 where the synthesized guide RNA
may bind to an unintended sequence allowing Cas9 to cut the genome at this off-target location.
This imprecision evolved to give a protective advantage to the host bacteria. Viruses evolve
rapidly and the ability of the bacteria’s CRISPR-Cas9 to recognize a new and slightly different
viral sequence will enable the bacteria to survive the viral attack.
So, the issue facing researchers is which technique, TALENs or CRISPR-Cas9, can better
limit this off-targeting. The technical challenges in controlling TALENs or CRISPR-Cas9 are
different. TALENs are a protein DNA recognition system, while CRISPR-Cas9 is an RNA DNA
recognition system. The chemistries of each are different. Also different are the nucleases in each
system, each with its own properties and specificities. At this time as pointed out by Pennisi
(2016a) and by Chandrasegaran & Carroll (2016) in their exhaustive, scholarly review of the
literature, TALENs are inherently more target specific.
The method with the most precision and least doubt about deleterious off-target effects is
more likely to be accepted by researchers, clinicians, governments, and the public. Regardless of
any potential benefits of genetic modifications of foods, regulators and the public must accept
these benefits, otherwise there may be little market for these enhanced products. Many people
are squeamish about any kind of genetic manipulation of their foods as shown by many
European countries that have banned cultivation of genetically modified crops (Chang 2017).
Related to this issue is how governments choose to regulate TALEN modified crops and inform
the public when they are consuming such products. The United States Department of Agriculture
currently distinguishes between plants that have had genes added to them, and plants where
genes have been simply removed or turned off. The latter are exempted from the regulations that
apply to genetically modified organisms (Hall 2016; Pennisi 2017b). Consumers now face the
prospect of eating foods with deleted genes, without their knowing this. On the other hand other
countries such as Canada have stricter regulations. Canada regulates any crop that has been
genetically modified.
Yet another issue is the patenting and licensing of this technology, and the disputes that may
arise. While so far there have been no hassles in TALENs patents (Hall 2016; Pennisi 2016a),
patent and licensing clashes regarding CRISPR-Cas9 may take years to resolve (Contreas &
Sherkow 2017; Cohen 2017)

Considering all the scientific, technical, agricultural, regulatory, medical, business,
commercial, socioeconomic, public perception and acceptance aspects of TALENs, many
different types of information resources need to be made available to patrons, depending on their
specific needs. We mediators need to be aware of and prepared to search multiple and diverse
sources of information.

Methods and results

The appropriate database search strategy for TALENs is:
"transcription activator like effector nuclease*" OR talen OR talens

The literature sometimes describes TALENs as "transcription activator-like effector
nuclease*". But searching this phrase should not be necessary because hyphens are read as
spaces in databases. This phrase is truncated to include the singular and plural using the wild
card symbol appropriate for the database or database family being searched. The abbreviated
terms talen and talens are included because even a quick perusal of the literature shows that in
the database records for many articles, only the abbreviation is present. Note that talen must not
be truncated. Doing so will retrieve many articles containing the word talent. Searching the terms
talen and talens will be precise only in databases that search titles, abstracts, and indexing terms
in their default fields. If the default search field also includes authors, many false drops will be
recovered because Talen and Talens are author surnames. These author name false drops can be
eliminated by adding:
NOT (talen[author] OR talens[author])
to your search. But this strategy is not advisable because it will exclude relevant articles on
TALENs where by coincidence an author has the name Talen or Talens.
The size and rapid growth of the TALENs literature is illustrated in Table 1. This data does
not include all the publications on TALENs, only those from journals that meet the strict criteria
for inclusion in this database (Testa 2016). Nonetheless, this figure clearly indicates the trend of
how this field is progressing. Even though TALENs were first reported in the literature in 2010
(Christian et al. 2010), a few articles mentioning TALENs are retrieved in earlier years, because

some authors in totally unrelated fields used TALEN as an abbreviation for a chemical substance
with a long name.

Table 1.TALENs articles in Science Citation Index Expanded (September 2017)
Year

Number of
Articles

2007

3

2008

1

2009

3

2010

3

2011

16

2012

53

2013

196

2014

333

2015

294

2016

308

2017

159

To show the diversity of databases containing references on TALENs and the references
unique to each database, a multi-file search was performed in selected databases in the STN
family of databases from 2010 to the present, September 2017. More databases than the ones
searched here are likely to contain references on TALENs. This search just emphasizes the many
databases that contain articles on TALENs, and how you can use this STN tool. The databases
included here are: BIOSIS Previews, CABA, Chemical Abstracts Plus, Chemical Business
NewsBase, Chemical Engineering And Biotechnology Abstracts – Verfahrenstechnische
Berichte, Chemical Industry Notes, Ei Compendex Dissertation Abstracts, Embase, Elsevier
BIOBASE, Food Science and Technology Abstracts, MEDLINE, Science Citation Index.
In these databases, the default search fields do not include authors. At this time, only
MEDLINE and Chemical Abstracts have controlled terms for TALENs. MEDLINE has the
newly introduced MeSH term "Transcription Activator-Like Effector Nucleases" with over 80
articles indexed with this term. Chemical Abstracts has a Chemical Abstracts Registry Number

(Weisgerber 1997) for TALENs (1400268-71-4), and this number is included in the search
because not only are there over 1400 articles in Chemical Abstracts indexed with this number,
but also because Chemical Abstracts, Registry Numbers can also be searched in these 7
databases; BIOSIS Previews, CABA, Chemical Business NewsBase, Chemical Engineering And
Biotechnology Abstracts – Verfahrenstechnische Berichte, Chemical Industry Notes, Embase,
and MEDLINE. Controlled terms may be added to other database as TALENs become more
widely studied.

=> file medline cin biosis dissabs fsta caba caplus compendex esbiobase ceaba-vtb embase cbnb
scisearch
=> search (transcription activator like effector nuclease? OR talen OR talens OR 1400268-71-4)
=> search L1 and py=>2010
=> set duporder file
=> duplicate remove L2

This series of command activates the duplicate removal feature in STN. This feature shows
the number of unique citations in each of the databases searched. This process first compares all
of the citations retrieved from these databases and eliminates all duplicates. The system then
collects and makes available for display all of the unique records that are present in the first
database on the list. Then the system looks into the second database on the list and notes which
records are not present in the first database. Then the third database is compared to the two above
it for unique records. The successive databases in the list are analyzed in the same manner. This
procedure displays the maximum number of unique records in the first database on the list, and
the least number of records from the last database.
Keeping in mind that in STN multi-file searches you can list the databases in any order, it
makes economic sense to print or display as many citations as possible from the database that has
the least expensive cost. The first database searched here is MEDLINE which costs only 41 cents
to display each citation with its abstract. This display cost rises in each succeeding database to
$19.45 for a single record with its abstract in Science Citation Index.
In this search the databases were searched from the least expensive to the most expensive
based on their per record display cost. But when choosing the database order, the searcher needs

to consider other costs such as connect hour costs, and search term costs and hourly cost options
in Chemical Abstracts Plus and Chemical Industry Notes. The search and display costs for any
STN database can readily and inexpensively be obtained with these commands when logged on
to STN:
=> file stnguide
=> s databasename/dbn;d cost
When searching any subject we need to see if the database contains a controlled term for that
subject. The database’s thesaurus can be searched for controlled terms. Another way to find
controlled terms is to perform a search that focuses on TALENs by limiting the above search to
article titles, and then examining the index terms to see if a relevant controlled term has been
applied.
This multi-file search in STN (Table 2) shows that even databases where references on
TALENs would not be expected, like the engineering database EI Compendex, have unique
references. So searchers need to consider all databases available to them especially from vendors
that have multi-file search capabilities. Such searching can also be done in databases from the
large and diverse number of databases provided by EBSCO Information Services (2017). While
duplicates are automatically removed when searching, the number of references unique to each
database is not tabulated.

Table 2 TALENs coverage in selected STN databases
Database

Number of unique citations

MEDLINE

1252

Chemical Industry Notes

3

BIOSIS Previews

841

Dissertation Abstracts

57

Food Science and Technology Abstracts

5

CABA

55

Chemical Abstracts Plus

1058

EI Compendex

10

Elsevier BIOBASE

35

Chemical Engineering And Biotechnology Abstracts

2

Embase

804

Chemical Business NewsBase

34

Science Citation Index

145

Since TALENs are being applied to crops, one would expect the United States Department of
Agriculture’s free database, AGRICOLA (https://agricola.nal.usda.gov/) to contain pertinent
articles. This database currently contains more than 100 articles on TALENs.
Since genetic engineering generates regulatory issues, we can expect that TALENs may also
generate such issues. Good places to check how the U.S. government is regulating or planning to
regulate TALENs are the Code of Federal Regulations (McKinney 2006) and its daily update the
Federal Register (Relyea 2011). The documents from these publications along with documents
and records from many other federal agencies can readily be searched in the Advanced Search
Mode at the Search Government Publications link at FDsys – Federal Digital System
(https://www.gpo.gov/fdsys/search/home.action). As of September 2017 the Code of Federal
Regulations currently has no entries on TALENS, while the Federal Register has more than 80
entries. However many of these are false drops where talen is the name of a company. This
database gives you the option of selecting a range of dates (TALENs were first reported in 2010)
and the ability to select entries from the relevant government agencies; the Food and Drug
Administration and the Department of Health and Human Services. Furthermore, the gateway to
U.S. government’s science information, https://www.science.gov/, has hundreds of references on
TALENs.
Newspapers are also an abundant source of articles on TALENs. Searching the full name for
TALENs yields a manageable number of newspaper reference in the Lexis-Nexis database. But
the search terms talen or talens yields hundreds with many false drops. Adding a subject specific
search term will eliminate nearly all of the false drops.
Regarding the important area of patents, nearly all patent searches need to be a combination
of text terms along with appropriate classification codes (Simmons & Kaback 1996). To show
the challenge of finding correct classification codes for TALENs, a search performed in
September 2017 in PATENTSCOPE (World Intellectual Property Organization 2017) searching
just the full name for TALENs and limiting the search to titles yielded 19 entries. But the
classification codes for these patents that clearly focus on TALENs showed no clear pattern and

contained no terms that suggest TALENs. Furthermore, a search in the Cooperative Patent
Classification (Espacenet 2017), the current official classification system in the world’s major
countries, for both the abbreviated and full names for TALENs retrieved several codes, but none
specifically mention TALENs. Apparently TALENs is cross referenced to these codes.
Consequently it is difficult for non-experts to know which of these terms need to be included in a
search. Furthermore, several different and intricate patent databases must be searched to insure
that all patents in any area are retrieved (Simmons & Kaback 1996). So, while any experienced
searcher can readily retrieve nearly all relevant articles in bibliographic databases, given the
challenge of finding the correct classification terms and the intricacies of the patent databases,
we must heed the still pertinent caveat of Nancy Lambert, among many others, who advise that
in many situations it is best to turn to patent searching experts (Shrode 1997).
Regarding books, Books In Print (http://www.booksinprint.com/) searching from the advent
of TALENs in 2010 to the present lists just these three books on TALENs.
Kuhn R, Wurst W, Wefers B, editors. 2016. TALENs: Methods and Protocols. New York:
Humana Press.

Yamamoto T, editor. 2015. Targeted Genome Editing Using Site-Specific Nucleases ZFNs,
TALENs, and the CRISPR/Cas9 System. New York: Springer.

Doudna JA, Sontheimer EJ, editors. 2014. The Use of CRISPR/cas9, ZFNs, TALENs in
Generating Site Specific Genome Alterations. Amsterdam: Elsevier.
This small number of books is not a disadvantage to researchers in this field. Rather it
confirms that most researchers in both established and developing fields in the biological and
chemical sciences rely on scientific journals as their primary source of knowledge. In journal
articles published in both the established field of structural biology and in the then developing
field of combinatorial chemistry fewer than 6% of the cited references were to books (Lascar &
Mendelsohn 2001; Barnett 2002).

Conclusion

Because of ongoing uncertainties about public and regulatory acceptance of TALENs,
researchers need to be aware of all issues related to genetic engineering. In addition their
literature needs will go well beyond just the scientific and technical sources, and should also
include vital and relevant information about other genetic engineering aspects of TALENs.
Librarians and information professionals need to take advantage of these many varied and
diverse resources on TALENs to adequately, efficiently, and best serve their patrons.
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